Assessing drug costs for use in comparative effectiveness research
نویسندگان
چکیده
منابع مشابه
Comparative effectiveness and comparative costs.
Kilbridge correctly points out that comparative effectiveness research (CER) does not require cost data. It should also be pointed out, however, that the composition of the quality-adjusted life-year (QALY) gain of one intervention over another—whether the QALY gain is achieved mainly in the dimension of longevity or in the dimension of quality of life—has real consequences in terms of comparat...
متن کاملcomparative analysis of the use of hedges & emphatics in english and persian academic research articles of sociology & psychology
چکیده ندارد.
15 صفحه اولUse of comparative effectiveness research in drug coverage and pricing decisions: a six-country comparison.
Comparative effectiveness research (CER) has assumed an increasing role in drug coverage and, in some cases, pricing decisions in Europe, as decision-makers seek to obtain better value for money. This issue brief comparatively examines the use of CER across six countries--Denmark, England, France, Germany, the Netherlands, and Sweden. With CER gaining traction in the United States, these intern...
متن کاملMethods in comparative effectiveness research.
Comparative effectiveness research (CER) seeks to assist consumers, clinicians, purchasers, and policy makers to make informed decisions to improve health care at both the individual and population levels. CER includes evidence generation and evidence synthesis. Randomized controlled trials are central to CER because of the lack of selection bias, with the recent development of adaptive and pra...
متن کاملAssessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development.
Comparative-effectiveness research (CER) aims to produce actionable evidence regarding the effectiveness and safety of medical products and interventions as they are used outside of controlled research settings. Although CER evidence regarding medications is particularly needed shortly after market approval, key methodological challenges include (i) potential bias due to channeling of patients ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2013
ISSN: 1098-3015
DOI: 10.1016/j.jval.2013.03.488